, Volume 11, Issue 1, pp 24–33

Therapy for Parkinson’s Disease: What is in the Pipeline?


DOI: 10.1007/s13311-013-0242-1

Cite this article as:
Stocchi, F. Neurotherapeutics (2014) 11: 24. doi:10.1007/s13311-013-0242-1


Despite advances in the treatment of Parkinson’s disease there are still many unmet needs, including neuroprotection, treatment of motor complications, treatment of dyskinesia, treatment of psychosis, and treatment of nondopaminergic symptoms. In this review, I highlight the obstacles to develop a neuroprotective drug and some of the treatment strategies recently approved or still in clinical trials designed to meet these unmet needs.


Parkinson’s diseasetreatmentpipeline

Supplementary material

13311_2013_242_MOESM1_ESM.docx (29 kb)
ESM 1(DOCX 28 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2013

Authors and Affiliations

  1. 1.Institute for Research and Medical CareIRCCS San RaffaeleRomeItaly